NEXTCURE INC

NXTCNASDAQ

🏆 #4747 by market capEarnings Nov 3US Equity

$4.90▼ $0.22 (−4.58%)

Market closed · at close

🔔

Track NXTC

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.6%

7d▲ 2.4%

14d▼ 18.1%

30d▼ 24.1%

ytd▼ 65.9%

1y▼ 16.7%

🏦Market Cap

$20M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

0.8x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $4.88 – $4.94
52-Week Range: $1.55 – $15.74
Volume: $3.25B
Avg Volume: $3.53B
Shares Outstanding: 4.1M
Next Earnings: Nov 14, 2026

Fundamentals Snapshot

Annual Revenue: $27M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: 0.8x
EPS (TTM): $-10.27
Dividend Yield: —
Dilution (1yr): +50.2%

Why Investors Own NXTC

✓High-growth profile — revenue up -8.6% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NEXTCURE INC

NXTC

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$58M▼ −3.6% YoY

Free Cash Flow

−$50M▲ +20.2% YoY

Shares Outstanding

3.5M▲ +50.2% YoY

Net Cash

$21M▼ −$949K YoY

StockOtter · stockotter.space

About NEXTCURE INC

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

🦦